Korea's Boryung Pharma Seeking MNCs To Sell Hypertension Product Abroad
This article was originally published in The Pink Sheet Daily
Executive Summary
Boryung hopes to find alternatives like out-licensing for Kanarb in order to get around the expense of meeting EU and U.S. manufacturing standards.